Results 41 to 50 of about 655,147 (306)

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. [PDF]

, 2015
Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant morbidity and mortality from cardioembolic complications like stroke.
Acharya, Tushar, Deedwania, Prakash
core   +1 more source

More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. [PDF]

, 2018
© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the ...
Farag M, Hirsh J, Ibanez B, Mega JL, Park KW, Suh JW, Valgimigli M   +6 more
core   +3 more sources

Factor Xa Inhibitors [PDF]

, 2016
Factor Xa represents an attractive target for antithrombotic drugs as blockade of factor Xa permits inhibition of both the extrinsic and intrinsic coagulation pathways. Several factor Xa inhibitors, such as rivaroxaban, apixaban and edoxaban, have been approved for certain conditions, and are also in clinical development for other indications.
Eduard Shantsila, Gregory YH Lip
openaire   +1 more source

Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis

Frontiers in Cardiovascular Medicine, 2022
BackgroundNon-vitamin K antagonist oral anticoagulants (NOACs) showed a benefit-risk profile superior to that of warfarin in atrial fibrillation (AF) patients with mild to moderate chronic kidney disease. However, the effectiveness and safety of NOACs in
Wenhao Li, Yanxia Zhou, Siqi Chen, Dewang Zeng, Haidong Zhang   +4 more
doaj   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm, AC Skanes, AG Turpie, AJ Camm, AK Kakkar, AT Cohen, B Laulicht, BF Gage, BI Eriksson, BI Eriksson, BI Eriksson, BI Eriksson, BS Stambler, C Kearon, CB Granger, CT Ruff, DE Salazar, G Agnelli, G Agnelli, G Lu, G Raskob, G Raskob, H Masumoto, H Zahir, Henri Bounameaux, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Stampfuss, JH Alexander, JI Weitz, JL Mega, K Ogata, KL Furie, LT Grip, M Crowther, M Hori, M Pirmohamed, MR Lassen, MR Lassen, MR Lassen, MR Lassen, MR Patel, MS Bathala, MU Zafar, N Chung, N Matsushima, R Caterina De, R Caterina De, RP Giugliano, S Kaatz, S Schulman, S Schulman, S Schulman, SE Kimmel, SJ Connolly, SJ Connolly, SJ Connolly, SZ Goldhaber, T Fuji, T Fuji, T Fukuda, T Hulle van der, T Mikkaichi, T Wilke, T Yamashita, TI Verhoef, W Mueck, Y Falck-Ytter, Y Kuroda   +72 more
core   +1 more source

Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections

American Journal of Cardiovascular Drugs, 2020
Human factor Xa (FXa) is a serine protease of the common coagulation pathway. FXa is known to activate prothrombin to thrombin, which eventually leads to the formation of cross-linked blood clots. While this process is important in maintaining hemostasis,
Rami A. Al‐Horani
semanticscholar   +1 more source

Identification of a 3-Alkylpyridinium Compound from the Red Sea Sponge Amphimedon chloros with In Vitro Inhibitory Activity against the West Nile Virus NS3 Protease. [PDF]

, 2018
Viruses are underrepresented as targets in pharmacological screening efforts, given the difficulties of devising suitable cell-based and biochemical assays.
Duggan, Brendan M, Emwas, Abdul-Hamid, Gerwick, William H, Kharbatia, Najeh, Kremb, Stephan, O'Rourke, Aubrie, Raji, Misjudeen, Sioud, Salim, Voolstra, Christian R   +8 more
core   +3 more sources

Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation

Research and Practice in Thrombosis and Haemostasis, 2020
Andexanet alfa (andexanet) is a modified human factor Xa (FXa) approved for anticoagulation reversal in patients with life‐threatening bleeding treated with rivaroxaban or apixaban.
Genmin Lu, Joyce Lin, K. Bui, J. Curnutte, P. Conley   +4 more
semanticscholar   +1 more source

Coagulation and anticoagulation in idiopathic pulmonary fibrosis [PDF]

, 2015
Idiopathic pulmonary fibrosis (IPF) is an incurable, progressive interstitial lung disease with a prognosis that is worse than that of many cancers. Epidemiological studies have demonstrated a link between IPF and thrombotic vascular events.
Crooks, Michael G., Hart, Simon P.
core   +3 more sources

Synthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo[3,2,1-ij]Quinolin-2(1H)-one as New Inhibitors of Factor Xa and Factor XIa

Molecules, 2020
Coagulation factor Xa and factor XIa are proven to be convenient and crucial protein targets for treatment for thrombotic disorders and thereby their inhibitors can serve as effective anticoagulant drugs.
Nadezhda Novichikhina, Ivan Ilin, Anna Tashchilova, Alexey Sulimov, Danil Kutov, Irina Ledenyova, Mikhail Krysin, Khidmet Shikhaliev, Anna Gantseva, Ekaterina Gantseva, Nadezhda Podoplelova, Vladimir Sulimov   +11 more
doaj   +1 more source